Published • loading... • Updated
Prostate cancer blood test detects twice as many cases
The multicomponent test detected 90% of clinically significant cancers versus 74% for PSA, while keeping specificity similar, researchers reported.
- In a secondary analysis of the STHLM3-MRI trial, the Stockholm3 test identified more clinically significant prostate cancers than standard PSA screening while missing fewer cases during the 2-year follow-up.
- Between 2018 and 2020, researchers analyzed data from 12,670 men who participated in the original STHLM3-MRI study, randomizing those with abnormal results to systematic biopsy or MRI-targeted procedures.
- Stockholm3 detected 90% of clinically significant cancers versus 74% for PSA, while demonstrating a 10% false-negative rate compared to 26% for PSA, and missing fewer cancers per 1,000 men screened.
- Thorgerdur Palsdottir, PhD, of the Karolinska Institutet, stated the test offers "a favorable balance" for biopsy decisions, though implementation depends on costs ranging from $550 to $750 in European markets.
- The study was limited by a 2-year follow-up; researchers emphasized that longer-term investigation is needed to evaluate survival and cause-specific mortality, though integrating the test could improve screening efficiency if findings are confirmed.
Insights by Ground AI
5 Articles
5 Articles
New blood test detects more high-risk prostate cancer cases
A new blood test may make it easier to detect the most dangerous forms of prostate cancer early. In a study from Karolinska Institutet, the Stockholm3 blood test detected more clinically significant cancer cases than the PSA test, without subjecting more men to unnecessary testing. The study is published in the Annals of Internal Medicine.
Multicomponent Test Tops PSA for Clinically Significant Prostate Cancers
(MedPage Today) -- A multicomponent blood-based biomarker test that combines prostate-specific antigen (PSA) with additional plasma protein biomarkers, a polygenic risk score, and clinical variables identified more clinically significant prostate...
·New York, United States
Read Full Article
Coverage Details
Total News Sources5
Leaning Left0Leaning Right1Center3Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
C 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium
